Geraldine began her career in a research and development parent pharmaceutical company (Negma-Lerads / Steba Biotech) as a Technico-Regulatory Pharmacist coordinating CMC projects to develop chemical, semi-synthetic and biotechnological molecules and associated medical devices for completion of the pre-clinical and clinical phases (up to Phase 3) for the Europe (IMPD), US (IND) and Canada (CTA) zones.

She then turned her focus to post-approval as Regulatory Affairs Manager of a post-MA product portfolio at BMS – UPSA in liaison with drug manufacturers.

She subsequently developed her techno-regulatory skills for ten years as a Regulatory and Pharmaceutical Affairs Consultant in the pharmaceutical unit of a renowned firm (A.R.C. Pharma).

She was responsible for regulatory and pharmaceutical advice, initial Marketing Authorization (Modules 1 and 3) and/or variation applications, MA renewals, the associated registration strategy, due diligence on product sales and managing pharmaceutical projects, especially in the context of site transfers. She also supported clients in opening and operating pharmaceutical establishments with exploitant status.

She has been able to develop her network of experts and speakers by launching annual two-day seminars on topical regulatory and pharmaceutical subjects.

Géraldine aimed to establish her own consulting and expertise firm in regulatory and pharmaceutical affairs, called ‘ATESSIA.’ The goal is to introduce a fresh, customer-centric approach to meet the specific expertise needs of healthcare industry professionals. In line with this commitment to excellence, Atessia has pursued ISO 9001 certification, embodying a continuous improvement initiative in its services

Then, in 2021, in order to complete our service offering, she developed a new entity, ‘AMARYLYS‘, which is positioned to delegate consultants within the healthcare industries in the same fields of activity.